Meeting Information - The company will hold its second extraordinary general meeting of shareholders in 2025 on September 17, 2025, at 14:30 [1] - Shareholders can participate either through on-site voting or online voting, with online voting available from 9:15 to 15:00 on the same day [1][2] - Shareholders must choose one voting method, and duplicate votes will be counted based on the first submission [1] Attendance and Voting Rights - All shareholders registered by the close of trading on the record date are entitled to attend the meeting and vote [1] - The meeting will also include company directors, supervisors, senior management, and appointed legal witnesses [2] - Proposals will require more than 50% approval from the voting rights held by attending shareholders [2] Registration Process - Individual shareholders must present their ID and shareholder account card for registration, while corporate shareholders must provide additional documentation [3] - Remote shareholders can register via mail or fax, ensuring to fill out the registration form accurately [3][5] Voting Procedures - Shareholders can vote through the Shenzhen Stock Exchange trading system or the internet voting system [7] - Specific procedures for online voting are provided, including identity verification requirements [7] Additional Information - Contact details for inquiries are provided, including a contact person and phone number [5] - Attachments include detailed voting procedures, authorization letters, and registration forms for shareholders [6][7]

Core Viewpoint - Fujian Guangshentang Pharmaceutical Co., Ltd. plans to transfer equity and increase capital in its subsidiary Guangsheng Zhonglin Biotechnology Co., Ltd. with a pre-investment valuation of 2.5 billion RMB, while the company will waive its preferential rights [1][3][20] Transaction Overview - The total investment amount for the capital increase is 191.35 million RMB, with Guangsheng Zhonglin's registered capital increasing from 388.5 million RMB to 418.236 million RMB [1][4] - The company will hold a 75.3163% stake in Guangsheng Zhonglin after the transaction, maintaining it as a controlled subsidiary [4][20] - The transaction requires approval from the shareholders' meeting [4] Investment Details - The investment will be made by Jinan Taishen Investment Partnership and Huaxin Shiheng, with respective contributions of 141.35 million RMB and 50 million RMB [3][20] - The equity transfer involves the sale of shares from Fuzhou Aotai Phase Five and Phase Six Investment Partnerships for a total of 58.65 million RMB [3][20] Financial Impact - The transaction aims to enhance Guangsheng Zhonglin's capital strength to support the development of innovative drugs, particularly for hepatitis treatment [20] - Guangsheng Zhonglin's innovative drugs GST-HG131 and GST-HG141 are included in the list of breakthrough therapeutic varieties by the National Medical Products Administration [20] Strategic Importance - The transaction aligns with the company's strategy to accelerate the research and development of innovative drugs and improve its operational capabilities [20] - The company believes that the capital increase will help attract talent and enhance research efficiency, ultimately leading to the commercialization of core innovative products [20]

Group 1 - The board of directors of Fujian Guangshentang Pharmaceutical Co., Ltd. held its 11th meeting of the 5th session on September 1, 2025, in Fuzhou, Fujian Province, with all 8 directors present [1][2]. - The board approved a proposal regarding the transfer of equity and capital increase of a controlling subsidiary, with a unanimous vote of 8 in favor and no opposition or abstentions [1][2]. - The board also approved a proposal to convene the second extraordinary general meeting of shareholders in 2025, with the same unanimous voting results [1][2]. Group 2 - The details of the proposals and meeting outcomes will be disclosed in the company's announcements published in various financial newspapers and on the official website [2]. - The meeting complied with the requirements of the Company Law and the company's articles of association [1]. - The board meeting was chaired by Chairman Li Guoping [1].

证券代码：300436 证券简称：广生堂 公告编号：2025062 福建广生堂药业股份有限公司 关于控股子公司股权转让及增资扩股暨 公司放弃优先权的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、福建广生堂药业股份有限公司（以下简称"公司"）创新药控股子公司 福建广生中霖生物科技有限公司（以下简称"广生中霖"或"目标公司"）拟以 投前整体估值 25 亿元进行增资，各方合计增资金额 19,135.1351 万元认购广生 中霖新增注册资本 2,973.60 万元，同时广生中霖股东福州奥泰五期投资合伙企 业（有限合伙）（以下简称"奥泰五期"）、福州奥泰六期投资合伙企业（有限 合伙）（以下简称"奥泰六期"）拟以广生中霖投前整体估值 17.5 亿元将各自 持有的部分广生中霖股权以合计 5,864.8649 万元进行转让（以下简称"本次交 易"或"本次增资"）。本次交易，公司放弃优先购买权和优先认缴出资权，本 次交易完成后广生中霖仍为公司控股子公司，不会导致公司合并报表范围发生变 更。 2、本次交易不构成关联交易，不构成《上市公司重大资产重组管理办法 ...

证券代码：300436 证券简称：广生堂 公告编号：2025063 福建广生堂药业股份有限公司 关于召开 2025 年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 根据《公司法》和《公司章程》的有关规定，经福建广生堂药业股份有限公 司（以下简称"公司"）第五届董事会第十一次会议审议通过，决定于 2025 年 9 月 17 日召开公司 2025 年第二次临时股东大会，现将会议有关事项通知如下： 一、会议召开的基本情况 1、股东大会届次：2025 年第二次临时股东大会 2、会议召集人：公司董事会 3、会议召开的合法、合规性：经公司第五届董事会第十一次会议审议通过， 公司召开 2025 年第二次临时股东大会；会议召集程序符合有关法律、行政法规、 部门规章、规范性文件和公司章程的规定。 4、会议召开的日期、时间： （1）现场会议召开时间：2025 年 9 月 17 日（星期三）14:30 （1）在股权登记日持有公司股份的股东。 （2）网络投票时间： 1）通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 9 月 17 日 9: ...

福建广生堂药业股份有限公司 证券代码：300436 证券简称：广生堂 公告编号：2025061 关于第五届董事会第十一次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 具体内容详见公司披露于《证券时报》《中国证券报》《上海证券报》《证 券日报》和巨潮资讯网 www.cninfo.com.cn 的《关于控股子公司股权转让及增资 扩股暨公司放弃优先权的公告》。 （二）审议通过《关于提请召开2025年第二次临时股东大会的议案》 表决结果：有效表决票数8票，同意8票，反对0票，弃权0票。 具体内容详见公司披露于《证券时报》《中国证券报》《上海证券报》《证 券日报》和巨潮资讯网 www.cninfo.com.cn 的《关于召开 2025 年第二次临时股 东大会的通知》。 1 福建广生堂药业股份有限公司（以下简称"公司"）第五届董事会第十一次 会议于 2025 年 8 月 26 日以邮件、短信等形式发出通知，于 2025 年 9 月 1 日在 福建省福州市闽侯县福州高新区乌龙江中大道 7 号海西高新技术产业园创新园 二期 16 号楼 ...

Group 1 - The company received an inquiry letter from the Shenzhen Stock Exchange regarding its application for a specific stock issuance on June 13, 2025 [1] - The company, along with relevant intermediaries, conducted a thorough study and response to the inquiry letter, updating the prospectus and application documents accordingly [1][2] - The issuance of stocks to specific targets requires approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission, with uncertainties regarding the approval timeline [2] Group 2 - The company disclosed the updated documents on August 29, 2025, on the Giant Tide Information Network [2] - The company emphasizes the importance of timely information disclosure based on the progress of the stock issuance matter [2]

Group 1 - The company received an inquiry letter from Shenzhen Stock Exchange regarding its application for a private placement of shares on June 13, 2025 [1] - The company, along with relevant intermediaries, conducted a thorough study and response to the inquiry letter, updating the prospectus and application documents accordingly [1][2] - The issuance of shares to specific targets requires approval from the Shenzhen Stock Exchange and registration consent from the China Securities Regulatory Commission, with uncertainties regarding the approval timeline [2] Group 2 - The company disclosed updates and revisions to the inquiry response and application documents on August 29, 2025 [2] - The company commits to timely information disclosure based on the progress of the share issuance matter [2]

Core Viewpoint - The innovative pharmaceutical stocks experienced a significant rebound, with Huahai Pharmaceutical and Kangchen Pharmaceutical both hitting the daily limit up, indicating strong market interest and investor confidence in the sector [1] Industry Summary - The National Medical Products Administration of China reported that the country's pharmaceutical industry ranks second globally, with approximately 30% of the world's innovative drugs currently under research [1] - Since the beginning of the 14th Five-Year Plan, a total of 387 pediatric drugs and 147 rare disease drugs have been approved for market, effectively addressing the medication needs of key populations [1] Company Summary - Huahai Pharmaceutical and Kangchen Pharmaceutical both reached the daily limit up, reflecting positive market sentiment towards their stock performance [1] - Other companies such as Puris, Duolai Pharmaceutical, Haoyuan Pharmaceutical, Huana Pharmaceutical, Medisi, Lifang Pharmaceutical, and Guangshengtang also saw stock increases, with some rising over 5% [1]

Core Viewpoint - Fujian Guangshentang Pharmaceutical Co., Ltd. is undergoing a stock issuance process, facing inquiries from the Shenzhen Stock Exchange regarding its financial matters and business operations [1] Financial Performance - The company reported revenues of 385.77 million yuan, 422.71 million yuan, 441.46 million yuan, and 97.61 million yuan over the reporting periods, with net profits of 132.18 million yuan, -354.23 million yuan, -199.54 million yuan, and -30.42 million yuan, indicating continuous losses [2] - The shift from generic to innovative drugs has led to increased R&D expenses and a decline in gross margins due to the inclusion of antiviral drugs in the national centralized procurement list, resulting in a 33.33% decrease in drug sales prices in 2023 compared to 2022 [2] - The gross margins over the last three years were 18.54%, 2.59%, and 8.57% [2] Procurement and Inventory - The procurement amounts from the top five suppliers were 39.34 million yuan, 97.64 million yuan, 79.83 million yuan, and 7.89 million yuan, with respective proportions of 39.86%, 56.57%, 60.53%, and 50.64% of total procurement [3] - The company has adopted a sales-driven production model, with significant increases in prepayments due to the sales of its product, Taizhongding [3] - Inventory values at the end of each period were 68.66 million yuan, 111.48 million yuan, 114.48 million yuan, and 121.13 million yuan, with a substantial increase in inventory impairment provisions expected due to product expiration [3] R&D and Financial Ratios - The number of R&D personnel decreased from 112 to 76, while R&D expenses were 185.46 million yuan, 132.96 million yuan, 44.05 million yuan, and 6.10 million yuan, with a declining R&D expense ratio [4] - The asset-liability ratios were 36.07%, 64.74%, 72.42%, and 73.45%, with a significant increase in 2023 due to financial liabilities recognized from a subsidiary's capital increase [4] - The liquidity ratios (current and quick) were consistently below industry averages, indicating potential liquidity challenges [4] Fundraising Projects - The company plans to raise 976.87 million yuan, with allocations of 598.38 million yuan for innovative drug R&D, 88.49 million yuan for traditional Chinese medicine industrialization, and 290 million yuan for working capital [5] - The innovative drug R&D project includes two drugs for chronic hepatitis B treatment, with significant capital expenditures planned for their development [5] - The traditional Chinese medicine project aims to acquire drug approvals for new products, with an expected internal rate of return of 23.22% [5] Previous Fundraising - Previous fundraising of 514 million yuan has been fully utilized, with some funds redirected due to unmet expectations from prior projects [6] - The company faces challenges in transitioning to innovative drugs, but successful implementation of fundraising projects could provide new growth opportunities [6]